The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.

Rheumatoid Arthritis Clinical Trial

— EASE PAIN  

Official title:

The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05913817
• Other study ID #: JAMP-AVT02-001
• Status: Recruiting
• Start date: January 9, 2023
• Est. completion date: November 13, 2024

Study information

• Verified date: June 2023
• Source: Jamp Pharma Corporation
• Contact: Dara Shahrokh, Ph.D.
• Phone: 6475235301
• Email: dshahrokh[@]jamppharm.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of the Phase IV study is to investigate the effects of both Volume and Citrate on Injection Site Pain (ISP), adherence, patient satisfaction, Quality of Life, and Disease Assessment in the Canadian Adalimumab Market. The phase IV study is an observational, pan-Canadian, multidisciplinary study aiming to enroll 600 patients across 50-70 sites across 3 different Therapeutic Areas (GI, Rheum, Derm).

Description:

The current phase 4 study seeks to assess the real-world injection experience, utilization, satisfaction, effectiveness, safety, and tolerability of treatment with AVT-02 (SIMLANDI™) in patients when switching from low-concentration adalimumab Humira® or another adalimumab biosimilar to high-concentration adalimumab SIMLANDI™ for the management of certain gastroenterological (IBD, including CD or UC); rheumatological (including RA, AS, or PsA); or dermatological conditions (including HS or PsO).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 600
• Est. completion date: November 13, 2024
• Est. primary completion date: September 18, 2024
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patient aged 18 years or older at the time of consent.

2. Patient has been diagnosed with CD, UC, RA, AS, PsA, HS, or PsO for at least 6 months.

3. Patient must be a current user of Humira® or another low-concentration adalimumab biosimilar, with treatment initiated at least 6 months prior to screening.

4. One of the following:

1. Treating physician is considering switching from Humira® to SIMLANDI™,

2. Treating physician is considering switching from an adalimumab biosimilar (not Humira®) to SIMLANDI™.

3. Treating physician has switched from Humira® or Humira® biosimilar to SIMLANDI™ within the past 3 months.

5. Patient must be willing to keep using the same type of injector when switching from

their previous adalimumab treatment to SIMLANDI™:

1. Pre-filled to pre-filled switch,

2. Autoinjector to autoinjector switch.

6. Access to commercial SIMLANDI™.

7. Patient or patient's legal/authorized representative agrees to sign informed consent and participate in the study.

Exclusion Criteria:

1. Patients previously treated with SIMLANDI™ or another high-concentration adalimumab biosimilar.

2. Patients that, in the opinion of the investigator, have any condition that may impair their ability to participate in the study.

3. Any current or history of any condition that, in the opinion of the investigator, participation in the study may increase the risk to the patient.

4. Patients for whom treatment with adalimumab may be contraindicated (e.g., patients with demyelinating disorders).

5. Patients with moderate to severe heart failure, as indicated by New York Heart Association (NYHA) class >= 3.

6. Patients with severe infections such as sepsis, tuberculosis, or opportunistic infections.

7. Patients with history of recurrent infection or with underlying conditions which may predispose them to infections.

8. Patients with known hypersensitivity to SIMLANDI™ or its excipients.

9. Patients who are unable to secure reimbursement for SIMLANDI™.

10. Patient anticipates not being available for follow-up assessments as required for adequate management.

11. Active participation in or enrollment in an interventional trial.

12. Patient or patient's legal/authorized representative cannot or will not sign informed consent.

Related Conditions & MeSH terms

• Ankylosing Spondylitis
• Arthritis
• Arthritis, Psoriatic
• Crohn Disease
• Hidradenitis
• Hidradenitis Suppurativa
• Plaque Psoriasis
• Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Spondylitis
• Spondylitis, Ankylosing
• Ulcerative Colitis

Intervention

Biological:
• AVT02 (Alvotech Biosimilar to Adalimumab)
Phase IV Study

Locations

Country	Name	City	State
Canada	JAMP Pharma Corporation	Montréal	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Jamp Pharma Corporation

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in injection site pain after the first dose of high-concentration adalimumab (AVT-02) as measured by the Visual Analog Scale (VAS); 2 weeks after Humira Injection (can be 1 week for certain indications such as HS).	Baseline injection site pain will be defined as the VAS score recorded during the last dose of the low-concentration adalimumab prior to switching to AVT-02.	At 2 Weeks
Secondary	Change from baseline in injection site pain after every injection of the high-concentration adalimumab (AVT-02) as measured by VAS during the 180 days of the study.	Baseline injection site pain will be defined as the VAS score recorded during the last dose of the low-concentration adalimumab prior to switching to AVT-02.	At Every AVT-02 Injection up to 180 Days.
Secondary	Patient perception of change in injection site pain (5-point Likert) after the first dose of high-concentration adalimumab (AVT-02) compared to Humira® or another low-concentration adalimumab biosimilar.	A five-point Likert scale of patient perception of change in injection site pain after the first dose of high-concentration adalimumab (AVT-02).	Once a month up to 180 Days.
Secondary	Distribution of missed doses of AVT-02.	Adherence to treatment when switching from Humira® or another adalimumab biosimilar to AVT-02.	At Every AVT-02 Injection up to 180 Days.
Secondary	Change from baseline in overall satisfaction with the injection (7-point Likert) during the 180 days of the study after switching from Humira or another low-concentration adalimumab to AVT-02.	A seven-point Likert scale of patient satisfaction.	At Every AVT-02 Injection up to 180 Days.
Secondary	Change from baseline in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Index Score during the 180 days of the study after switching from Humira or another low-concentration adalimumab to AVT-02.	A questionnaire assessing health-related quality of life covering five dimensions (mobility, ability to self-care, ability to undertake usual activities, pain/discomfort, and anxiety/depression) with five levels of severity for each dimension (no problems, slight problems, moderate problems, severe problems, and extreme problems).	At days 30, 60, 90, 120, 150, and 180.
Secondary	Change from baseline in physician disease assessment during the 180 days of the study after switching from Humira or another low-concentration adalimumab to AVT-02	Asses the Physician Global Assessment (PGA) at baseline and at Day 180.	At Baseline and at Day 180.
Secondary	Change from baseline in patient-reported disease assessment during the 180 days of the study after switching from Humira or another low-concentration adalimumab to AVT-02	Asses the Patient Global Assessment of Disease Activity (PtGA) at baseline and at Day 180.	At Baseline and at Day 180.
Secondary	Change from baseline in health care utilization during the 180 days of the study.	A questionnaire assessing healthcare resource utilization related to the patient indication, including medical events and treatments experienced by the patient in the last month.	At days 30, 60, 90, 120, 150, and 180.